|
|
|
|
|
Methazolamide
drug data and news
Methazolamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Methazolamide | ||
| Brand Names/Synonyms | MZM; Methazolamide; Methenamide; Naptazane; Neptazane; Neptazaneat | ||
| Indication | For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride. | ||
| Mechanism Of Action | Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. | ||
| Methazolamide News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Diuretics; Carbonic Anhydrase Inhibitors; ATC:S01EC05 | ||
| Absorption | Methazolamide is well absorbed from the gastrointestinal tract. | ||
| Interactions |
Interactions for Methazolamide: Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia,
tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic
anhydrase inhibitors. | ||
| Toxicity | Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-(3-methyl-5-sulfamoyl-3H-1,3,4-thiadiazol-2-ylidene)ethanamide | ||
| Chemical Formula | C5H8N4O3S2 | ||
| Molecular Weight | 236.274 g/mol | ||
| Smiles String | CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C | ||
| Melting Point | 213.5 °C | ||
| Water Solubility | 3500 mg/L | ||
| State | Solid (white crystalline powder) | ||
| LogP/Hphobicity | 0.231 | ||
| Isoelectric Point | 7.3 | ||
| Biotransformation | Not Available | ||
| Half Life | 14 hours | ||
| Protein Binding [%] | 55% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Methazolamide.html http://www.rxlist.com/cgi/generic2/methaz.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00740 | ||
| CAS Registry Number | 554-57-4 | ||
| KEGG Compound ID | C07764 | ||
| PubChem ID | SID:9966 | ||
| PharmGKB ID | PA450413 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2245882 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |